Bristol Myers Squibb: FDA legt PDUFA-Datum für iberdomide-NDA fest

Auszug aus der Quelle

EX-99.1 2 a2026q1ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 30, 2026 Document Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2026 Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead • First quarter revenues increased 3% (+1% Ex-FX) to $11.5 billion ◦ Growth Portfolio revenues increased 12% (+9% Ex-FX) to $6.2 billion • GAAP EPS was $1.31 and non-GAAP EPS was $1.58; Both figures include net impact of $(0.03) due to the Acquired IPRD charges and licensing income • Reaffirms 2026 financial guidance with revenues of ~$46.0 billion to $47.5 billion; Non-GAAP EPS range of $6.05 to $6.35, with total revenues and non-GAAP EPS trending toward the upper end of the ranges (PRINCE

SEC 8-K

Mehr zu diesem Asset

Entscheidungsrelevant

13. Aug. 2026

00:00

BMYBristol-Myers Squibb

Bristol-Myers Squibb Co. · FDA genehmigt Zenbexus (iberdomide)

FDA-ZulassungFDA-NeuzulassungenEintrag öffnen1 Aktualisierung